Phase 2 Alzheimer's Disease Trial, Not Yet Recruiting NCT07192913 Sponsor: University of Arizona Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Not Yet Recruiting

NCT07192913
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with mild cognitive impairment (MCI), which is a noticeable but mild decline in memory or thinking skills.
  • People between the ages of 18 and 85 years old.
  • People who, or whose close contacts, have noticed and reported problems with memory or thinking.
  • People whose cognitive testing results meet specific MCI criteria — either one test score that falls notably below average, or a pattern of lower scores across one or more thinking/memory areas — as measured by a standard set of neuropsychological tests (confirm with trial site for details on which scoring method applies).
  • People who are right-handed.
  • People who speak English.
  • People who are able to attend daily sessions for approximately 15 days spread across a 6-month period.
  • People who have not been enrolled in another interventional study within the 6 months before starting this trial.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a medical reason that would make it unsafe to undergo transcranial magnetic stimulation (TMS, a non-invasive brain stimulation technique) or MRI brain scans.
  • People who have experienced a sudden or rapid worsening of their memory or thinking abilities.
  • People whose score on a specific telephone-based cognitive screening test (called the TICS) does not meet the required threshold (confirm with trial site for the specific score required).
  • People who have other neurological conditions, such as a history of stroke, significant head injuries, or multiple sclerosis.
  • People who have a psychiatric disorder — though stable late-life depression may be an exception due to its common occurrence alongside MCI (confirm with trial site).
  • People who are currently receiving cancer treatment, or who have other unstable or serious medical conditions that could independently affect memory or thinking.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 10 August 2026

Contact this trial

Principal Investigator: Ying-Hui Chou, Sc.D., University of Arizona

Phone: 520-626-7755

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
University of Arizona
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
1 July 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

NIH Toolbox

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 10 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov